Vitrolife interim report January - June 2003

2003-08-13 - 12:07

Vitrolife interim report January - June 2003 · Net sales for the group, after the last years divestment of business area Biosupportive Systems, amounted to SEK 48,8 million (62,5), and gross margin increased to 60% (50%), the group's net loss totalled SEK -6,6 million (-13,6). · Net sales for core activities increased by 23 % to a total of SEK 48.8 million (39.6) and gross result increased by 40 % to SEK 29.5 million (21.2), the operating result amounted to SEK 0.1 million (-14.0). · The group's net loss totalled SEK -4.3 million (-9.9). · Vitrolife received FDA marketing approval of EmbryoGlue® - a breakthrough in ART (Assisted Reproductive Technology) Gothenburg, August 13, 2003. Vitrolife AB (Publ) For further information, please contact: Vitrolife Acting CEO: Magnus Nilsson Tel: +46 31 721 80 00 Mobile +46 708 22 80 61 mnilsson@vitrolife.com CFO and IR agent: Margareta Fischer Tel: +46 31 721 80 00 Mobile: +46 708 22 80 13 mfischer@vitrolife.com Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and four wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado), A-Life Ltd. (Edinburgh, Scotland), and A-Life Inc. (Newport Beach, California). The group's operations focused on three geographic areas. · Europe/Middle East · North America · Rest of the World Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/08/13/20041110BIT21330/wkr0001.pdf The full report in Swedish